- Home
- SDOT vs BTAI Comparison
SDOT vs BTAI Comparison
Compare SDOT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDOT
- BTAI
- Stock Information
- Founded
- SDOT 2014
- BTAI 2017
- Country
- SDOT United States
- BTAI United States
- Employees
- SDOT N/A
- BTAI N/A
- Industry
- SDOT Restaurants
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- SDOT Consumer Discretionary
- BTAI Health Care
- Exchange
- SDOT Nasdaq
- BTAI Nasdaq
- Market Cap
- SDOT 8.0M
- BTAI 8.3M
- IPO Year
- SDOT 2020
- BTAI 2018
- Fundamental
- Price
- SDOT $0.92
- BTAI $5.48
- Analyst Decision
- SDOT
- BTAI Strong Buy
- Analyst Count
- SDOT 0
- BTAI 4
- Target Price
- SDOT N/A
- BTAI $40.00
- AVG Volume (30 Days)
- SDOT 685.6K
- BTAI 22.4M
- Earning Date
- SDOT 08-14-2025
- BTAI 08-12-2025
- Dividend Yield
- SDOT N/A
- BTAI N/A
- EPS Growth
- SDOT N/A
- BTAI N/A
- EPS
- SDOT 1.07
- BTAI N/A
- Revenue
- SDOT $726,598,000.00
- BTAI $868,000.00
- Revenue This Year
- SDOT $12.76
- BTAI N/A
- Revenue Next Year
- SDOT $5.54
- BTAI $328.13
- P/E Ratio
- SDOT $0.85
- BTAI N/A
- Revenue Growth
- SDOT 18.91
- BTAI N/A
- 52 Week Low
- SDOT $0.84
- BTAI $1.17
- 52 Week High
- SDOT $5.70
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- SDOT 39.75
- BTAI 67.45
- Support Level
- SDOT $0.85
- BTAI $1.30
- Resistance Level
- SDOT $0.98
- BTAI $8.08
- Average True Range (ATR)
- SDOT 0.07
- BTAI 1.23
- MACD
- SDOT 0.01
- BTAI 0.33
- Stochastic Oscillator
- SDOT 40.54
- BTAI 61.65
About SDOT Sadot Group Inc.
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.